| PI3K抑制剂与其他药物联用克服耐药性的研究进展 |
| |
| 引用本文： | 贾成舒,王均伟,李慧,朱启华,葛亦然,徐云根. PI3K抑制剂与其他药物联用克服耐药性的研究进展[J]. 中国药科大学学报, 2017, 48(5): 523-528 |
| |
| 作者姓名： | 贾成舒 王均伟 李慧 朱启华 葛亦然 徐云根 |
| |
| 作者单位： | 中国药科大学药物化学系,中国药科大学药物化学系,中国药科大学药物化学系,中国药科大学药物化学系,中国药科大学药物化学系,中国药科大学药物化学系 |
| |
| 基金项目： | 国家自然科学基金资助项目(No.81502928)；江苏高等学校优秀科技创新团队资助项目(2015) |
| |
| 摘 要： | 磷脂酰肌醇3-激酶(PI3K)是细胞内重要的信号传导分子，在细胞存活、增殖和分化过程中发挥着关键的调节作用。PI3K抑制剂在肿瘤治疗方面的研究取得了重大的进展，然而，PI3K抑制剂耐药性的出现，影响了其在临床上的长期疗效。为了克服PI3K抑制剂的耐药性，临床上发展了多种合理的药物组合方法来提高疗效，克服耐药性。本文就PI3K抑制剂与其他药物联用以克服耐药性的研究进展进行了综述。
|
| 关 键 词： | 磷脂酰肌醇3-激酶；PI3K抑制剂；抗肿瘤；药物联用；耐药性 |
Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance |
| |
| JIA Chengshu,WANG Junwei,LI Hui,ZHU Qihu,GE Yiran and XU Yungen. Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2017, 48(5): 523-528 |
| |
| Authors: | JIA Chengshu WANG Junwei LI Hui ZHU Qihu GE Yiran XU Yungen |
| |
| Abstract: | Phosphoinositide 3-kindase, an important signal transduction molecule in cells, plays a key role in the process of cell survival, proliferation and differentiation. Significant progress has been made in the treatment of cancer with PI3K inhibitors, yet the drug resistance of PI3K inhibitors affects their long-term efficacy in clinical treatment. In order to overcome the drug resistance, a variety of rational combined therapies have been developed. In this paper, the research progress of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome the drug resistance were reviewed. |
| |
| Keywords: | phosphatidylinositol-3-kinase PI3K inhibitors antitumor drug combination resistance |
|
| 点击此处可从《中国药科大学学报》浏览原始摘要信息 |
|
点击此处可从《中国药科大学学报》下载全文 |
|
